VCG
PCRX icon

Vantage Consulting Group’s Pacira BioSciences PCRX Stock Holding History

Vantage Consulting Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-378
Closed -$23K – 1140
2020
Q4 		$23K Buy
+378
New +$22.1K ﹤0.01% 820

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vantage Consulting Group's PCRX Position: Q1 2021 in Review

Vantage Consulting Group sold out of Pacira BioSciences (PCRX) in Q1 2021, closing a stake of 378 shares — an estimated $23K sold.

Vantage Consulting Group first reported a position in PCRX in Q4 2020 and held it in 1 quarter. The position peaked at $23K in Q4 2020. 270 funds tracked by Wall St. Rank hold PCRX as of Q1 2021.

  • Vantage Consulting Group reported no remaining Pacira BioSciences position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 378 Pacira BioSciences shares in Q1 2021, an estimated $23K.
  • Vantage Consulting Group first reported a position in Pacira BioSciences in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Pacira BioSciences position peaked at $23K in Q4 2020.
  • 270 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.